Catalent (STU:0C8) Additional Paid-In Capital : €4,387 Mil(As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Catalent Additional Paid-In Capital?

Catalent's quarterly additional paid-in capital declined from Sep. 2023 (€4,426 Mil) to Dec. 2023 (€4,348 Mil) but then increased from Dec. 2023 (€4,348 Mil) to Mar. 2024 (€4,387 Mil).

Catalent's annual additional paid-in capital increased from Jun. 2021 (€3,490 Mil) to Jun. 2022 (€4,398 Mil) but then declined from Jun. 2022 (€4,398 Mil) to Jun. 2023 (€4,339 Mil).

Catalent Additional Paid-In Capital Historical Data

The historical data trend for Catalent's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Additional Paid-In Capital Chart

Catalent Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Additional Paid-In Capital

Get a 7-Day Free Trial

2,440.30

3,390.38

3,490.15

4,397.95

4,339.02

Catalent Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															4,387.00	4,339.02	4,426.39	4,348.41	4,387.48

Catalent Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Catalent Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Catalent's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalent (STU:0C8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (STU:0C8) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

CTLT:USA

Address

14 Schoolhouse Road, Somerset, NJ, USA, 08873

Website

https://www.catalent.com

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Catalent (STU:0C8) Headlines

No Headlines